Enoximone sulfoxide is a selective phosphodiesterase III (PDE3) inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. Enoximone prevents the degradation of cAMP by PDE, which prolongs signal transduction and its subsequent effects. It is used in patients with congestive heart failure.
Niacin hydrochloride is a water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is needed by the body for the formation of coenzymes NAD and NADP. It possesses PELLAGRA-curative, vasodilating, and antilipemic properties.
Quazinone is a selective inhibitor of phosphodiesterase 3 (PDE3) with positive inotropic and vasodilating properties.1,2 It induces relaxation of precontracted isolated human cavernous smooth muscle (IC50 = 4.2 μM).1 Quazinone (10-300 μg kg) increases myocardial contractile force in anesthetized open-chest dogs in a dose-dependent manner, as well as decreases systolic and diastolic blood pressure.2 It also inhibits DNA synthesis induced by the PDGF isoform PDGF-BB in bovine coronary artery smooth muscle cells in a concentration-dependent manner.3
Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist that effectively blocks both α- and β-adrenergic receptors, effectively producing antihypertensive and vasodilating effects [1].
Angiotensin II is a hormone that plays an important role in regulating blood pressure. Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor. Losartan is a mammalian AT1 receptor antagonist with a Ki value of 5-20 nM. In humans, losartan effectively controls hypertension while protecting renal function. Nitric oxide (NO) causes vasodilation and also inhibits platelet and neutrophil aggregation in the endothelium. NO-losartan A possesses similar anti-hypertensive effects to losartan, with the addition of the vasodilating effects of NO release.
ICI 153110 is an orally active phosphodiesterase inhibitor with both inotropic and vasodilating properties. It is designed for the treatment of congestive cardiac failure.
Isoxsuprine Free Base is a beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Zelandopam is a dopamine D1 agonist. Zelandopam is a potent stimulant of pancreatic exocrine secretion by acting on DA D1 receptors of the pancreas in dogs. Intravenous administration of Zelandopam produces renal vasodilating and diuretic/natriuretic effe
Arotinolol is a nonselective α β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. It is an antihypertensive agent.
Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.